KTTAW (Pasithea Therapeutics Corp. Warrants)
Insider Trading Activity
Every open-market purchase and sale reported by KTTAW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Coastlands Capital LP | 10%+ Owner | Buy | — | — |
| 2026-05-05 | LAWRENCE STEINMAN | Director | A | — | — |
| 2026-05-05 | Tiago Marques | Chief Executive Officer | A | — | — |
| 2026-05-05 | Kartik Krishnan | Chief Medical Officer | A | — | — |
| 2026-05-05 | Emer Leahy | Director | A | — | — |
| 2026-05-05 | Simon Dumesnil | Director | A | — | — |
| 2026-05-05 | Daniel H Schneiderman | Chief Financial Officer | A | — | — |
| 2026-05-05 | Alfred J Novak | Director | A | — | — |
| 2025-12-01 | LAWRENCE STEINMAN | Director | Buy | — | — |
| 2025-12-01 | Emer Leahy | Director | A | — | — |
| 2025-12-01 | Daniel H Schneiderman | Chief Financial Officer | A | — | — |
| 2025-12-01 | Simon Dumesnil | Director | Buy | — | — |
| 2025-12-01 | Tiago Marques | Chief Executive Officer | Buy | — | — |
| 2025-10-27 | Emer Leahy | Director | A | — | — |
| 2025-10-27 | Tiago Marques | Chief Executive Officer | A | — | — |
| 2025-10-27 | Daniel H Schneiderman | Chief Financial Officer | A | — | — |
| 2025-10-27 | Simon Dumesnil | Director | A | — | — |
| 2025-10-27 | LAWRENCE STEINMAN | Director | A | — | — |
| 2025-10-27 | Alfred J Novak | Director | A | — | — |
| 2025-05-14 | Tiago Marques | Chief Executive Officer | Sell | — | — |
| 2024-06-14 | Alfred J Novak | Director | A | — | — |
| 2024-04-05 | Tiago Marques | Chief Executive Officer | A | — | — |
| 2024-04-05 | Alfred J Novak | Director | A | — | — |
| 2024-04-05 | Graeme Martin Currie | Chief Development Officer | A | — | — |
| 2024-04-05 | Emer Leahy | Director | A | — | — |
| 2024-04-05 | Simon Dumesnil | Director | A | — | — |
| 2024-04-05 | LAWRENCE STEINMAN | Director | A | — | — |
| 2024-04-05 | Daniel H Schneiderman | Chief Financial Officer | A | — | — |
| 2024-03-01 | Emer Leahy | Director | A | — | — |
| 2024-03-01 | LAWRENCE STEINMAN | Director | A | — | — |
| 2024-03-01 | Alfred J Novak | Director | A | — | — |
| 2024-03-01 | Graeme Martin Currie | Chief Development Officer | A | — | — |
| 2024-03-01 | Daniel H Schneiderman | Chief Financial Officer | A | — | — |
| 2024-03-01 | Tiago Marques | Chief Executive Officer | A | — | — |
| 2024-03-01 | Simon Dumesnil | Director | A | — | — |
| 2023-06-06 | LAWRENCE STEINMAN | Director | — | — | — |
| 2023-06-06 | LAWRENCE STEINMAN | Director | Buy | — | — |
| 2022-11-28 | LAWRENCE STEINMAN | Director | A | — | — |
| 2022-11-28 | Tiago Marques | Chief Executive Officer | A | — | — |
| 2022-11-22 | LAWRENCE STEINMAN | Director | A | — | — |
| 2022-11-17 | Simon Dumesnil | Director | A | — | — |
| 2022-10-26 | LAWRENCE STEINMAN | Director | A | — | — |
| 2022-10-24 | Alfred J Novak | Director | A | — | — |
| 2022-10-21 | Tiago Marques | Chief Executive Officer | A | — | — |
| 2022-10-19 | David Delaney | — | Buy | — | — |
| 2022-10-17 | LAWRENCE STEINMAN | Director | A | — | — |
| 2022-10-12 | Daniel H Schneiderman | Chief Financial Officer | A | — | — |
| 2022-09-30 | Camac Fund, LP | — | Buy | — | — |
| 2022-09-06 | Camac Capital, LLC | — | Buy | — | — |
| 2022-08-31 | Eric Shahinian | — | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,835,035 | — |
| — | — | 1,788,415 | — |
| — | — | 1,724,058 | — |
| — | — | 1,617,329 | — |
| — | — | 227,521 | — |
| — | Director | 199,691 | — |
| — | Chief Executive Officer | 73,334 | — |
| — | — | 54,644 | — |
| — | Director | 35,833 | — |
| — | Director | 33,333 | — |
| — | Chief Financial Officer | 26,667 | — |
| — | Director | 750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KTTAW quote page; the site-wide leaderboard is on the insider transactions hub.